Researchers have developed a deep learning model that can spot longitudinal changes in patients' brain imaging that could be indicative of cancer recurrence.
Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways.
Reviewing data from more than 6,000 patients, researchers found little evidence of the "obesity paradox" observed elsewhere. Underweight TAVR patients, however, may face some significant long-term risks.
The Millipede 088 was designed to treat large vessel occlusion stroke patients by “ingesting” the blood clot as opposed to dragging it through the patient’s blood vessels.
India-based Meril Life Sciences has been manufacturing its Myval transcatheter heart valves for years, but the technology has not yet gained FDA approval. This latest head-to-head comparison included data from more than 1,000 TAVR patients.
Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.
There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes.
Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis.